pDUO-mMD1/RP105

A plasmid coexpressing the murine MD1 and RP105 genes

Catalog code: pduo-mmd1rp105

https://www.invivogen.com/pduo-md1-rp105

For research use only

Version 20H26-MM

PRODUCT INFORMATION

Contents

- 20 µg of pDUO-mMD1/RP105 provided as DNA
- 2 x 1 ml blasticidin at 10 mg/ml

Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store blasticidin at 4°C or -20°C. The expiry date is specified on the product label.

Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

Toll-Like receptors (TLRs) play a critical role in early innate immunity to invading pathogens by sensing microorganisms. These evolutionary conserved receptors, homologues of the Drosophila Toll gene, recognize highly conserved structural motifs only expressed by microbial pathogens, called pathogen-associated microbial patterns (PAMPs). PAMPs include various bacterial cell wall components such as lipopolysaccharides (LPS), peptidoglycans and lipopeptides, as well as flagellin, bacterial DNA and viral double-stranded RNA. Stimulation of TLRs by PAMPs initiates a signaling cascade that involves a number of proteins, such as MyD88 and IRAK. This signaling cascade leads to the activation of the transcription factor NF-κB which induces the secretion of pro-inflammatory cytokines and effector cytokines that direct the adaptive immune response.

To date ten human and twelve murine TLRs have been characterized, TLR1 to TLR10 in humans, and TLR1 to TLR9, TLR11, TLR12 and TLR13 in mice, the homolog of TLR10 being a pseudogene. In many instances, TLRs require the presence of a co-receptor to initiate the signaling cascade. One example is TLR4 which interacts with MD2 and CD14 to induce NF-κB in response to LPS stimulation.

pDUO is an expression vector designed to co-express two TLRs or TLR-related genes known to interact with each other.

The genes cloned into pDUO comprise the coding sequence (without introns) from the ATG to the Stop codon.

PLASMID FEATURES

- **Murine MD1** (486 bp) / **Murine RP105** (1983 bp)

MD1 and RP105 (CD180) are physically associated with each other and are involved in the response to LPS. RP105 is a TLR-related protein, that acts as both an LPS sensor and a regulator of B cell proliferation[1]. Stable expression of MD-1 was shown to induce an increase in cell surface RP105 on a cell line that expresses RP105 alone, suggesting that MD1 is important for efficient cell surface expression of RP105[2]. When induced by LPS, the RP105/MD1 complex regulates B-cell proliferation, antibody production, and B7.2/CD86 up-regulation[3].

- **hFerH and hFerL composite promoters:** Ferritin is a 24 subunit protein composed of two subunit types, termed H (heavy) and L (light), which perform complementary functions in the protein. Ferritin is ubiquitously expressed. Its synthesis is highly regulated by the iron status of the cell. The iron regulation is achieved at the translational level through the interaction between the iron-responsive element (IRE), located in the 5' untranslated region (5'UTR) of the ferritin mRNAs, and the iron regulatory protein[4]. To eliminate the iron regulation of the ferritin promoters, the 5'UTR of FerH and FerL have been replaced by the 5'UTR of the mouse and chimpanzee elongation factor 1 (EF1) genes, respectively.
- **SV40 enhancer** which is comprised of a 72-base-pair repeat allows the enhancement of gene expression in a large host range. The enhancement varies from 2-fold in non-permissive cells to 20-fold in permissive cells. Furthermore, the SV40 enhancer is able to direct nuclear localization of plasmids[5].
- **CMV enhancer:** The major immediate early enhancer of the human cytomegalovirus (HCMV), located between nucleotides -118 and -524, is composed of unique and repeated sequence motifs. The HCMV enhancer can substitute for the 72-bp repeats of SV40 and is severalfold more active than the SV40 enhancer[6].
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA. The efficiency of this signal was first described by Carswell *et al.*[7]
- **pMB1 ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.
- **FMDV IRES:** The internal ribosome entry site of the Foot and Mouth Disease Virus enables the translation of two open reading frames from one mRNA with high levels of expression[8].

TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3622-3480
E-mail: info@invivogen.com

• **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
• **Bsr (blasticidin resistance gene):** The *bsr* gene from *Bacillus cereus* encodes a deaminase that confers resistance to the antibiotic Blasticidin. In bacteria, *bsr* is expressed from the constitutive *E. coli* EM7 promoter. In mammalian cells, *bsr* is transcribed from the human FerH composite promoter as a polycistronic mRNA and translated via the FMDV IRES.
• **EF1 pAn** is a strong polyadenylation signal. InvivoGen uses a sequence starting after the stop codon of the EF1 cDNA and finishing after a bent structure rich in GT.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H_2O. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied at 10 mg/ml in HEPES buffer.

References

1. **Miyake K. *et al.*, 2000.** Innate recognition of lipopolysaccharide by Toll-like receptor 4/MD-2 and RP105/MD-1. J Endotoxin Res, 6(5):389-91.
2. **Miyake K. *et al.*, 1998.** Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression. J Immunol, 161(3):1348-53.
3. **Nagai Y. *et al.*, 2002.** Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. Blood, 99(5):1699-705.
4. **Eisenstein RS. & Munro HN. 1990.** Translational regulation of ferritin synthesis by iron. Enzyme 44(1-4):42-58.
5. **Dean DA. *et al.*, 1999.** Sequence requirements for plasmid nuclear import. Exp. Cell. Res. 253:713-22.
6. **Boshart M. *et al.*, 1985.** A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 141(2):521-30.
7. **Carswell S. & Alwine JC. 1989.** Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol. Cell Biol. 10: 4248-4258.
8. **Ramesh N *et al.*, 1996.** High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site. Nucleic Acids Res. 24(14):2697-700.


pDUO-mMD1mRP105 v02
(8174 bp)
SdaI (6)
NdeI (182)
SnaBI (288)
BspEI (520)
HpaI (7993)
ScaI (7818)
MfeI (7669)
BstEII (7032)
Eco47III (7000)
XbaI (6674)
BsrGI (6530)
EcoRV (6331)
NcoI (6160)
BspHI (6099)
XcmI (5965)
SmaI (5719)
SandI (4973)
NotI (4946)
BssHII (4928)
SphI (4883)
SphI (4811)
SdaI (4676)
PacI (4667)
ApaLI (4341)
PacI (3927)
MfeI (3832)
HpaI (3823)
NheI (3683)
SspI (3628)
XhoI (3469)
PshAI (3249)
XcmI (2563)
PmeI (2354)
Bsu36I (2045)
DraIII (2038)
BspEI (1679)
NcoI (1673)
DraIII (1509)
SmaI (1323)
EF1a(h) p(A)
hCMV enh
FerL(h) prom
BsrS2
EM7
IRES (FMDV)
mMD-1
EF1(ch) 5'UTR
mRP105
5'UTR/Int.I (m)EF1
FerH(h) prom
SV40 enh(3)
ori pMB1
SV40 p(A) mod.
200


SdaI (6)
NdeI (182)
SnaBI (288)
BspEI (520)
SmaI (1323)
DraIII (1509)
BspEI (1679)
NcoI (1673)
DraIII (2038)
Bsu36I (2045)
PmeI (2354)
XcmI (2563)


PshAI (3249)
XhoI (3469)
SspI (3628)
NheI (3683)
HpaI (3823)
MfeI (3832)
PacI (3927)
ApaLI (4341)
PacI (4667)
SdaI (4676)
SphI (4811)
SphI (4883)
BssHII (4928)
NotI (4946)
SandI (4973)
SmaI (5719)
XcmI (5965)
BspHI (6095
NcoI (6160)


EcoRV (6331)
6301 CATTAGATTTGGCATCATTCTGAGACAGGATATCAGAAAGCTGTTTCTGGACATAACTCTGATGGCAAAAGGCTCTTCTATTCTGAACTACTCCTATCCC
67 nI leArgPheGlyI leI leLeuArgGlnAspI leArgLysLeuPheLeuAspI leThrLeuMetAlaLysGlySerSerI leLeuAsnTyrSerTyrPro
6401 CTTTGTGAGGAGGACCAGCCCAAGTTCTCATTCTGTGGAAGAAGAAAAGGAGAACAGATATACTATGCCGGCCCTGTCAATAACCCTGGACTTGATGTTC
101 LeuCysGluGluAspGlnProLysPheSerPheCysGlyArgArgLysGlyGluGlnI leTyrTyrAlaGlyProValAsnAsnProGlyLeuAspValP
BsrGI (6530)
6501 CACAGGGAGAATATCAGCTCTTGCTGGAACTGTACAATGAAAACCGTGCTACTGTGGCTTGTGCCAATGCCACTGTCACCTCCTCCTGAGCATGGTCTGC
134 roGlnGlyGluTyrGlnLeuLeuLeuGluLeuTyrAsnGluAsnArgAlaThrValAlaCysAlaAsnAlaThrValThrSerSer•••
XbaI (6674)
6601 AAGGAAATGCTAGGAGCAGGTTTCCCCAATGACACAAAACGTGCAACTTGAAACTCCGCCTGGTCTTTCCAGGTCTAGAGGGGTAACACTTTGTACTGCG
6701 TTTGGCTCCACGCTCGATCCACTGGCGAGTGTTAGTAACAGCACTGTTGCTTCGTAGCGGAGCATGACGGCCGTGGGAACTCCTCCTTGGTAACAAGGAC
6801 CCACGGGGCCAAAAGCCACGCCCACACGGGCCCGTCATGTGTGCAACCCCAGCACGGCGACTTTACTGCGAAACCCACTTTAAAGTGACATTGAAACTGG
Eco47III (70
6901 TACCCACACACTGGTGACAGGCTAAGGATGCCCTTCAGGTACCCCGAGGTAACACGCGACACTCGGGATCTGAGAAGGGGACTGGGGCTTCTATAAAAGC
BstEII (7032)
7001 GCTCGGTTTAAAAAGCTTCTATGCCTGAATAGGTGACCGGAGGTCGGCACCTTTCCTTTGCAATTACTGACCCTATGAATACACTGACTGTTTGACAATT
7101 AATCATCGGCATAGTATATCGGCATAGTATAATACGACTCACTATAGGAGGGCCACCATGAAGACCTTCAACATCTCTCAGCAGGATCTGGAGCTGGTGG
1 MetLysThrPheAsnI leSerGlnGlnAspLeuGluLeuValG
7201 AGGTCGCCACTGAGAAGATCACCATGCTCTATGAGGACAACAAGCACCATGTCGGGGCGGCCATCAGGACCAAGACTGGGGAGATCATCTCTGCTGTCCA
15 luValAlaThrGluLysI leThrMetLeuTyrGluAspAsnLysHisHisValGlyAlaAlaI leArgThrLysThrGlyGluI leI leSerAlaValHi
7301 CATTGAGGCCTACATTGGCAGGGTCACTGTCTGTGCTGAAGCCATTGCCATTGGGTCTGCTGTGAGCAACGGGCAGAAGGACTTTGACACCATTGTGGCT
48 sI leGluAlaTyrI leGlyArgValThrValCysAlaGluAlaI leAlaI leGlySerAlaValSerAsnGlyGlnLysAspPheAspThrI leValAla
7401 GTCAGGCACCCCTACTCTGATGAGGTGGACAGATCCATCAGGGTGGTCAGCCCCTGTGGCATGTGCAGAGAGCTCATCTCTGACTATGCTCCTGACTGCT
82 ValArgHisProTyrSerAspGluValAspArgSerI leArgValValSerProCysGlyMetCysArgGluLeuI leSerAspTyrAlaProAspCysP
7501 TTGTGCTCATTGAGATGAATGGCAAGCTGGTCAAAACCACCATTGAGGAACTCATCCCCCTCAAGTACACCAGGAACTAAACCTGAATTAATTCGCTAGG
115 heValLeuI leGluMetAsnGlyLysLeuValLysThrThrI leGluGluLeuI leProLeuLysTyrThrArgAsn•••
MfeI (7669)
7601 ATTATCCCTAATACCTGCCACCCCACTCTTAATCAGTGGTGGAAGAACGGTCTCAGAACTGTTTGTTTCAATTGGCCATTTAAGTTTAGTAGTAAAAGAC
7701 TGGTTAATGATAACAATGCATCGTAAAACCTTCAGAAGGAAAGGAGAATGTTTTGTGGACCACTTTGGTTTTCTTTTTTGCGTGTGGCAGTTTTAAGTTA
ScaI (7818)
7801 TTAGTTTTTAAAATCAGTACTTTTTAATGGAAACAACTTGACCAAAAATTTGTCACAGAATTTTGAGACCCATTAAAAAAGTTAAATGAGAAACCTGTGT
HpaI (7993)
7901 GTTCCTTTGGTCAACACCGAGACATTTAGGTGAAAGACATCTAATTCTGGTTTTACGAATCTGGAAACTTCTTGAAAATGTAATTCTTGAGTTAACACTT
8001 CTGGGTGGAGAATAGGGTTGTTTTCCCCCCACATAATTGGAAGGGGAAGGAATATCATTTAAAGCTATGGGAGGGTTTCTTTGATTACAACACTGGAGAG
8101 AAATGCAGCATGTTGCTGATTGCCTGTCACTAAAACAGGCCAAAAACTGAGTCCTTGGGTTGCATAGAAAGCTG